Shanghai HRAIN Biotechnology

Shanghai HRAIN Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development of next-generation cell therapies for cancer. Founded in 2015 by Dr. Zhang Tongcun, the company utilizes its proprietary CAR-T and TCR-T technology platforms to target both hematological malignancies and solid tumors. Its lead candidate, HR001, is a CD19-targeted CAR-T therapy currently in pivotal clinical trials for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. Beyond its lead programs, HRAIN is advancing a diverse pipeline that includes bispecific CAR-Ts, armored CAR-Ts with safety switches, and universal off-the-shelf (UCAR-T) products. The company operates a state-of-the-art GMP manufacturing facility to support its clinical development and future commercialization efforts. HRAIN has secured significant backing from prominent venture capital firms, positioning it as a key player in the Chinese cell therapy landscape.